Combining immunotherapy with PARP inhibitors. Is it possible to find the way through?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combining immunotherapy with PARP inhibitors. Is it possible to find the way through?

Published:2024-09-13 Issue: Volume: Page:1-5
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Papageorgiou Georgios I¹^ORCID,Skouteris Nikolaos²^ORCID,Eleftheriou Kleopatra³^ORCID,Kosmas Christos²^ORCID

Affiliation:

1. 2nd Medical Oncology Department, IASO General Clinic, Athens, Greece

2. Division of Medical Oncology & Hematopoietic Cell Transplant Unit, Department of Medicine, “Metaxa” Cancer Hospital, Piraeus, Greece

3. Pharmacy Department, IASO General Clinic, Athens, Greece

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/1750743X.2024.2398412

Reference30 articles.

1. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

2. Crosstalk between immune checkpoint and DNA damage response inhibitors for radiosensitization of tumors

3. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed

4. Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors

5. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP